Zerlasiran is our wholly owned siRNA (short interfering RNA) in development for high lipoprotein(a), or Lp(a), a genetically determined cardiovascular risk factor affecting around 20% of the world’s population.
Zerlasiran is a gene ‘silencing’ therapy – one that is designed to temporarily block a specific gene’s message that would otherwise trigger an unwanted effect. In this case, it aims to ‘silence’ LPA, a gene that tells the body to make a specific protein that is only found in Lp(a). By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks and strokes.
Learn More About Cardiovascular Disease Due to High Lp(a)